Biggest News Aggregation in the World

Page 41 - Roche Group News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roche Group. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roche Group Today - Breaking & Trending Today

First-Ever Clinical Trial Exclusively in Black and Hispanic / Latinx People Living With Multiple Sclerosis Shows Genentech's Ocrevus Effectively Manages Disease Activity | Region

Published: October 11, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 11, 2023--

Source: eagletribune.com

Lineage Announces Issuance of U.S. Patent Covering Proprietary Manufacturing and Differentiation Process for Retinal Pigmented Epithelial Cells

Published: October 11, 2023

Lineage Cell Therapeutics, Inc. , a clinical-stage biotechnology company developing allogeneic cell therapies for unmet medical needs, today announced that the United States Patent and Trademark...

Source: marketscreener.com

Futures Pointing To Continued Strength On Wall Street

Published: October 11, 2023

The major U.S. index futures are currently pointing to a modestly higher open on Wednesday, with stocks likely to extend the upward trend seen over the past few sessions.

Source: rttnews.com

Genentech's Ocrevus Twice-Yearly, 10-Minute Subcutaneous Injection Was Non-Inferior to Intravenous Infusion and Provided Near-Complete Suppression of Brain Lesions | Business

Published: October 11, 2023

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Oct 11, 2023--

Source: valdostadailytimes.com

Genentech's Vabysmo Maintained Vision Improvements With Extended Treatment Intervals Up to Four Months for People With Retinal Vein Occlusion (RVO) in Phase III Trials

Published: October 10, 2023

– Vabysmo showed robust and sustained retinal drying up to 72 weeks and a safety profile consistent with previous trials –– If approved by the FDA, RVO would be Vabysmo’s third indication in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME) –– Vabysmo is the first and only treat...

Source: pharmiweb.com